



Prevalence and distribution of human papillomavirus (HPV) serotypes of the anogenital region in adolescent boys and young men: a systematic review

Anna Pardali¹, Eleni Panagouli¹, Theodoros N. Sergentanis¹, Theodore Panoskaltsis², Maria Tsolia¹, Nikolaos Vlahos², Artemis Tsitsika^{1,*}

¹MSc Program “Strategies of Developmental and Adolescent Health”, School of Medicine, National and Kapodistrian University of Athens, Greece;

²Second Department of Obstetrics and Gynecology, Aretaieion Hospital, National and Kapodistrian University of Athens, School of Medicine

ABSTRACT

The objective of this study is to investigate the impact of HPV vaccinations on the prevalence of HPV serotypes on adolescent boys and young men through a systematic review. The search aimed for clinical studies in English up to 2022 concerning HPV serotyping of samples from randomly selected, non-high risk male participants, aged 11-25 with no underlying pathologies. The search resulted in 18 eligible articles among which 15 concerned unvaccinated and 3 concerned vaccinated young males. In 4 articles the participants were homosexual/bisexual, in 4 they were heterosexual while in the rest of the publications the sexual orientation of participants was mixed or unspecified. In about half of the articles, sample collection predated the initiation of national HPV vaccination programs for girls in the respective countries. In the selected articles, HPV seroprevalence varied significantly depending on vaccination rates and variability in methodology. Overall HPV prevalence was found to be high in most studies. Significant reduction of HPV vaccine-type prevalence was detected only in directly vaccinated adolescent boys and young men.

Key Words: HPV; adolescent boys; HPV vaccine; seroprevalence

Introduction

The Human Papilloma Virus (HPV) is the most widespread sexually transmitted infectious agent, which is responsible for causing a variety of skin and epithelial lesions in the anogenital area of males and females, including precancerous lesions and carcinogenesis (1). The HPVs are categorized in high- or low-risk types based on their tumorigenicity. Types 6, 11, 40, 42, 43, 44, 54, 61, 72, 81 are considered low-risk, non-oncogenic types and are usually responsible for low-grade histological lesions such as papillomas and warts. Among the high-risk oncogenic types are types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82 which can potentially cause high-grade histological lesions leading to cancers such as cervical and other procto-genital cancers as well as oropharyngeal cancers (2). It is estimated that 4.5% of all new cancer diagnoses are related to HPV infection. Cervical cancer constitutes 83% of these cases, while the largest percentage concerns women in low-income countries (3). Considering these findings, increased surveillance of HPV infections and systematic research on prevention strategies including the enhancement of vaccination programs are imperative.

Despite the availability of approved HPV vaccines since 2006-7 and their inclusion in national vaccination programs in over 107 of the 194 WHO member states as of June 2020, global vaccination coverage still remains low (4). However, even in countries where vaccination coverage does not exceed 50%, it has been found that vaccinations appear to reduce the prevalence of HPV and the rates of HPV-related neoplasms (5). In particular, according to the recent Cochrane systematic review on the efficacy and safety of vaccination of adolescent girls and young women up to 26 years of age, HPV vaccines were found to be highly effective in preventing cervical precancerous lesions (6). Therefore, the systematic investigation of vaccination protocols for their optimization as well as the identification of factors that may inhibit vaccination coverage is necessary.

The available prophylactic vaccines against HPV are the bivalent vaccine targeting HPV types 16, 18, the quadrivalent vaccine against types 6, 11, 16, 18 and the ninevalent vaccine against types 6, 11, 16, 18, 31, 33, 45, 52, 58 (7). According to the original WHO guidelines and protocols, national vaccination programs primarily targeted adolescent girls who are at 10 times higher risk of malignancy due to HPV infection than boys, while protection to boys should incur through herd immunity (8). Herd immunity

effects though, have been detected only in countries with very high vaccination coverage of women (9). Therefore, current studies on the effectiveness of herd immunity tend to emphasize on the need to expand vaccination programs so that they also include boys (9). Another argument for the need of a pangender vaccination approach is that even if herd immunity is developed, vaccinating women does not offer any protection to homosexual men (10). Moreover, the prevalence of HPV-related head and neck cancers is much higher in men than in women although the HPV types that are associated with the development of such cancers are included in the available vaccines (11). In several countries vaccination programs that also include adolescent boys are already implemented (12), while further systematic research on the necessity of pangender vaccinations in order to reduce the risk of HPV-related neoplasms, especially in males, is deemed necessary (13).

Considering the aforementioned, the need for systematic research on the restructuring and promotion of HPV vaccination programs that ensure adequate coverage of the male population is imperative. In this context, the main purpose of this systematic review is to investigate the effect of vaccination programs on the prevalence of different HPV types in adolescent boys and young men. The ultimate goal of this study is to evaluate the prevalence of HPV in the male population as well as the degree of protection provided to them through herd immunity due to the vaccination of girls. The results of the review will be discussed with a view to assessing the need to include adolescent males in national HPV vaccination programs.

Materials and Methods

The main aim of this systematic review was to investigate the effect of current vaccination programs on the prevalence of the various HPV types in adolescent boys and young men, emphasizing on the vaccine types. More specifically, the present study aimed to investigate fluctuations in the overall prevalence and distribution of HPV subtypes in males aged 11 to 25 years. The search for relevant articles was performed without a time limit until 12/2022 in order to select articles before and after 2006, when global HPV vaccination programs initiated. Possible changes in the distribution of HPV subtypes were examined in relation to the time of initiation of nation-

al vaccination programs in the country where each selected study was conducted, but also in relation to the age and sexual orientation of the participants. The main research question in this study is whether herd immunity resulting from vaccination of females also protects the male population or whether direct vaccination of boys is necessary. It is a research hypothesis that in studies conducted in countries where national vaccination programs for girls were implemented prior to the time of the study, the prevalence of HPV may also be different in men compared to studies conducted in unvaccinated female populations. Another research hypothesis is that the overall prevalence in male populations should show a decreasing trend in order to consider that vaccination programs so far have offered some degree of protection to males.

The search and selection of articles for this systematic review was performed in accordance with the PRISMA guidelines (14). Articles were searched through the international database PubMed based on the algorithm (HPV OR “human papilloma virus”) AND (adolescent OR teens) AND (serotypes OR types) AND (boys OR men OR male). According to the advanced search options of this database, only articles in the English language were retrieved. The eligibility of the retrieved articles was assessed in accordance to specific inclusion criteria. According to these criteria, eligible articles should exclusively include studies in a human model (cohort, observational, cross-sectional, etc.) and be conceptually compatible with the purpose of the study. The articles should concern male participants aged 11 to 25 years without diagnosed underlying pathological or infectious diseases such as neoplasms or HIV. Moreover, articles should concern randomly selected participants and not high-risk groups for HPV such as people with dermatological lesions and warts or people whose partners have been diagnosed with HPV. Finally, articles should present quantitative HPV serotyping data using the PCR method on anogenital swab samples or from urine samples. The references of the selected articles were also assessed for eligibility.

Results

The initial search through the PubMed database yielded 1133 which were then assessed against the aforementioned selection criteria according to the PRISMA specifications. As presented in the flow chart in figure 1, 642 articles were excluded due to obvious inconsistency with the objective of the study or for comprising literature reviews, meta-analyses, *in vitro* studies or studies in a non-human

model. A further 473 articles were excluded as they did not refer to males or the required age group or concerned high-risk participants or their sampling and serotyping methods were not compatible to the inclusion criteria of this study. The final number of selected articles that met the selection criteria was 18 (Figure 1). After examining the references of the selected articles, no additional articles were identified as the articles that met the search criteria were duplicates of those already selected during the initial search.




Figure 1. Flow chart of article selection according to PRISMA guidelines

The 18 selected articles included 4 cross-sectional studies, 11 observational studies, 1 randomized clinical trial and 2 cohort studies (Table 1). The studies in the selected articles date from 2004 to 2021 as no earlier studies were found that met the selection criteria. The selected studies involve participants from geographical areas of all continents. Regarding the purpose of the them aim to evaluate the prevalence of HPV and the factors that increase the risk of HPV infection. Among the selected studies, 10 exclusively examined HPV prevalence in male participants and 8 in male and female populations. The majority of studies (15) involved unvaccinated participants, 1 study involved vaccinated participants (15) while 2 studies included both vaccinated and unvaccinated participants(16; 17). In the majority of studies, the sexual orientation of the participants is not mentioned or considered, while 4 studies specifically examine men who have sex with men and 4 specifically examine heterosexual men (Table 2). Concerning sampling methods, in

5 studies HPV serotypes were identified in urine samples (17; 18; 19; 20; 21) while in the remaining 13 swab samples from the anogenital region were used. Another observation is that in 9 studies the start of the national vaccination program for girls in the country where the study was conducted was contemporary or later than the time of the study while in the other 9 it was earlier (Tables 3, 4).

An initial observation regarding the results of the studies is that in the studies where HPV serotypes were identified in a urine sample the range of rate values recorded was approximately sub-tenfold of the rates identified from anogenital swabs (Figure 2). It is therefore questionable whether the two sampling methods have comparable sensitivity as current literature suggests that HPV detection in men's urine is not as effective as detection in anogenital swabs (22). Regarding the age of the participants in the selected articles, it ranges from 11 to 25 years. In the context of this systematic review, it was considered appropriate to investigate the prevalence of HPV in this age range, considering the fact that the initiation of sexual activity in adolescence significantly increases the prevalence of HPV, while the maximum effects of this increase are detected in early adolescence (23).




Figure 2 Indicative values of total HPV prevalence from the selected articles in anogenital swab and urine samples

Among the selected articles, examining overall HPV prevalence and high- and low-risk subtypes separately for adolescent and early adolescent age groups, Sonnenberg *et al.*, (2013) (19) and Gargano *et al.*, (2017) (15) detected significant increase in early adolescence. In addition, Sonnenberg *et al.*, (2013) (19) point out that in men this increase remains constant while in women it decreases, an observation consistent with the fact that the virus has different behavior and resistance between the two sexes (24). Similar conclusions are reached by O'leary *et al.*, (2011) (21), according to which the prevalence of the virus is significantly higher in the age

group of 15-18 years compared to the age group of 11-14 years, so the proposed age to start vaccination she should be younger than 15 years old. Accordingly, Hussain *et al.*, (2012) (20) and Bianchi *et al.*, (2013) (18), estimate that the prevalence of HPV in boys under 13 years is minimal. A safe conclusion that is consistent with the current literature is that the optimum vaccination age of boys should be early adolescence in order to prevent an increase in the prevalence of the virus in adolescence and post-adolescence with the onset of sexual activity (23).

Regarding studies that included vaccinated participants (15; 16; 17), although limited, they conclude that direct vaccination of boys significantly reduces HPV prevalence. These findings clearly demonstrate the effectiveness of direct vaccination of young boys in reducing HPV infections as seen in current studies conducted in countries implementing widespread or pilot vaccination programs in men who have sex with men (25) but also in random populations of males (26). According to the same studies, however, these programs should be expanded in order to offer adequate protection to boys and young men. Regarding the sexual orientation of the participants, as mentioned above 4 studies specifically examine men who have sexual contacts with men as the population of these men has a higher HPV prevalence than heterosexual men (27). Both Chow *et al.*, (2021) (16) and Zou *et al.* (2016) (28) found a significantly higher prevalence of low-risk vaccine subtypes (6, 11) than high-risk subtypes (16, 18) possibly related to differences in subtype prevalence by site of infection as in anal HPV infections low-risk types are more common in men who have sex with men (28). Zou *et al.*, (2014) (28) detect a high prevalence of both high- and low-risk subtypes included in the 4v vaccine and highlight the need for prophylactic vaccinations at a fairly young age as the increase in viral prevalence is rapid with the onset of sexual activity of MSM boys. Nyitray *et al.*, (2011) (29) also found that HPV prevalence is higher in men who have sex with both women and men compared to exclusively gay and heterosexual men. They further pointed out that the distribution of subtypes and the factors influencing the prevalence of oncogenic types are different for heterosexual men (30). Regarding the selected articles that deal exclusively with heterosexual men, HPV prevalence is also high while Partridge *et al.* (2007) (31) also pointed out that the rate of occurrence is higher than in women, a fact that should be taken into account when planning vaccination programs. Accordingly, Vardas *et al.* (2011) (32) in an observational study of heterosexual

Table 1: Methodology and results of selected articles

article	year(s)	age	nationality	longitudinal	total HIV prevalence	prevalence of high-risk	prevalence of HIV at ages 15-19	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-89	90-94	95-99	sexual orientation
Chow et al., 2021	2011	17	1674/1	Age	seroprevalence		10.7%	5.3%	1.6%																	
Chow et al., 2021	2011	17	1674/1	Age	seroprevalence		6.4%	1.6%	4.1%																	
Wendland et al., 2020	2010	11-30	1424	Age	seroprevalence	4.10%	24.3%																			
Wittawatmongkol et al., 2019	2019	17-30	1077-10	Age	seroprevalence	4%	3%																			
Lehtinen et al., 2017	2017	18	18	Age	seroprevalence	4.3%	2.0%	4.8%	0%																	
Lehtinen et al., 2017	2017	18	18	Age	seroprevalence	14.0%	6%	5.8%	7.3%																	
Gargano et al., 2017	2017	14-19	14-19	Age	seroprevalence	14.1%	14.1%	14.1%	14.1%																	
Zou et al., 2016	2016	20	164/70	Age	seroprevalence			10.8%	6.9%																	
Zou et al., 2014	2014	20	164/70	Age	seroprevalence	3%	3%	10.8%																		
Blanchi et al., 2013	2013	11-14	107	Age	seroprevalence	11.1%	10.4%	10.4%																		
Sonnenberg et al., 2013	2013	15-19	15-19	Age	seroprevalence	16.7%	16.7%	16.7%																		
Wendland et al., 2010	2010	15-24	15-24	Age	seroprevalence	4.5%	14.9%	10.8%																		
Wendland et al., 2010	2010	15-24	15-24	Age	seroprevalence	2.3%	1.1%	0%																		
Hussain et al., 2012	2012	15-19	15-19	Age	seroprevalence	11.1%	11.1%	11.1%																		
O'Leary et al., 2011	2011	18-24	18-24	Age	seroprevalence	2%																				
Vardas et al., 2011	2011	18-24	18-24	Age	seroprevalence	4%	3%																			
Nyiray et al., 2011	2011	15-24	15-24	Age	seroprevalence	4%	3%																			
Nyiray et al., 2011	2011	15-24	15-24	Age	seroprevalence	4%	3%																			
Parada et al., 2010	2010	15-24	15-24	Age	seroprevalence	23%																				
Giuliano et al., 2008	2008	15-24	15-24	Age	seroprevalence	14.0%	14.0%	14.0%																		
Partridge et al., 2007	2007	15-24	15-24	Age	seroprevalence	24%	3%	0%																		
Shin et al., 2004	2004	15-24	15-24	Age	seroprevalence	6.7%	6.7%	1.6%																		

Table 2: Sexual orientation of participants in each study

article	sexual orientation
Chow et al., 2021	MSM
Wendland et al., 2020	
Wittawatmongkol et al., 2019	
Lehtinen et al., 2017	
Gargano et al., 2017	
Zou et al., 2016	MSM
Zou et al., 2014	MSM
Blanchi et al., 2013	
Sonnenberg et al., 2013	
Wendland et al., 2010	
Hussain et al., 2012	
O'Leary et al., 2011	
Vardas et al., 2011	MSW
Nyiray et al., 2011	MSW
Nyiray et al., 2011	MSM
Parada et al., 2010	MSW
Giuliano et al., 2008	
Partridge et al., 2007	MSW
Shin et al., 2004	

Table 4: Studies conducted after the start of a national vaccination program

article	study conducted in:	initiation of national vaccination program in:
Chow et al., 2021	2010-2012	2007
Chow et al., 2021	2010-2012	2007
Wendland et al., 2020	2016-2017	2014
Lehtinen et al., 2017	2010-2014	2007-2009
Lehtinen et al., 2017	2010-2014	2007-2009
Gargano et al., 2017	2013-2014	2006
Zou et al., 2016	2010-2012	2007
Zou et al., 2014	2010-2012	2007
Blanchi et al., 2013	2009-2010	2007-2008
Sonnenberg et al., 2013	2010-2012	2008
O'Leary et al., 2011	2008	2008

Table 3: Studies conducted prior to the initiation of a national vaccination program

article	study conducted in:	initiation of national vaccination program in:
Wittawatmongkol et al., 2019	2013-2014	2017
Wendland et al., 2010	2009	2010
Hussain et al., 2012	2011??	2016
Vardas et al., 2011	<2011	>2011
Nyiray et al., 2011	2005-2009	2006, 2012, 2014
Nyiray et al., 2011	2005-2009	2006, 2012, 2014
Parada et al., 2010	2002-2003	2012
Giuliano et al., 2008	2008-2005	2006
Partridge et al., 2007	2008-2006	2006
Shin et al., 2004	2002	2016

men on 5 continents found a high prevalence of all HPV types while pointing out that the prevalence of the virus did not seem to be affected by condom use or circumcision.

Likewise, Parada *et al.* (2010) (33) found the HPV prevalence of heterosexual young men in Mexico to be high and directly related to the prevalence in women, while the number of sexual partners was considered to be the main factor increasing the risk of HPV infection. A high prevalence was also observed in studies involving a random population of boys and young men selected regardless their sexual behavior. Thus, Wendland *et al.*, (2020)(34) και Wittawatmongkol *et al.*, (2019) (35) estimated an overall HPV prevalence of approximately 50% while the prevalence of high-risk types was approximately 30%. Wendland *et al.* (2020) (34) also detected a different distribution of the 4v vaccine subtypes between men and women, which does not support the theory of herd immunity. Giuliano *et al.*, (2008) (36) also pointed out that in young men the rate of infection and clearance is faster than in women. These results are consistent with international studies according to which the prevalence of HPV in men, the persistence of infection and the immune responses vary according to their sexual behavior (30).

Regarding the analysis of results in relation to the vaccination coverage of women, the prevalence of the high- and low-risk subtypes included in the vaccines did not appear to differ significantly in studies where the initiation of the national girls' vaccination program in the study country preceded the study comparing to studies that were implemented prior to the initiation of the respective vaccination programs. Moreover, across all the selected articles, the overall prevalence of HPV remains high among young sexually active men, regardless of women's vaccination coverage. The direct vaccination of young boys seems to have a significant effect on the prevalence of oncogenic and non-oncogenic HPV subtypes, while the design of unified national vaccination programs regardless of gender and sexual orientation may be the most effective approach to limiting HPV infections and their effects.

Discussion

Most of the studies on HPV in the current literature concern the diagnosis, treatment, and prevention of HPV infections in women. Accordingly, most health pro-

grams for the epidemiological control and prevention of HPV focus on women, while the role of men in the epidemiology of the virus tends to be overlooked. Consequently, studies focusing on the epidemiology and prevention of HPV in young men are limited and their results inconclusive. In addition, a large percentage of research on the epidemiology of HPV in men specifically concerns men who have sex with/and with men as they are a population group with a high prevalence of HPV that does not benefit from possible herd immunity due to vaccination of girls (10). Given the fairly high prevalence of the virus in men as well as the fact that men are often asymptomatic carriers and contribute to the spread of the virus by increasing the burden of the consequences of HPV infections in women, further systematic investigation of the epidemiology of HPV in men is deemed imperative (37).

According to this systematic review, it is concluded that the prevalence of the virus in adolescent and young male populations worldwide remains high. No changes in the prevalence of the HPV subtypes included in the vaccines were observed, which would imply herd immunity effects, while a significant reduction in overall virus prevalence was observed only in studies that included directly vaccinated boys (15;16;17). This observation is consistent with relevant recent studies confirming the reduction of HPV infection rates in vaccinated young boys which advocate the need to include young boys in national vaccination programs (10). Moreover, according to the relevant literature, reduction in the prevalence of high-risk HPV types in men has only been observed in countries with particularly high vaccination coverage of women (9;38). For example, according to a study in Britain where the vaccination coverage of girls exceeds 80%, a significant reduction was also observed in the rates of HPV infections of the oropharynx in men as a result of herd immunity (39). However, in the majority of studies on the effectiveness of herd immunity, it is found that it does not provide sufficient protection while the need to expand vaccination programs to young boys is highly emphasized (40).

Another observation to be discussed in this systematic review concerns the age of boys at which HPV prevalence increases rapidly as a result of the initiation of sexual activity and which should be the age limit for immunizing young boys. According to the results of the selected articles, an increase in the prevalence of the virus is observed in the age groups above 14 years, while in boys up to 13 years the prevalence of HPV is particularly low (20;21). Consequently, the ideal age for boys to be immunized is earlier than 13-14 years whi

which is consistent with the World Health Organization guidelines that health providers should encourage the initiation of vaccination at age 9- 12 (1). Moreover, it has been reported that men who have sex with men do not seem to benefit at all from the herd immunity that to some extent is provided to heterosexual men by the vaccination of girls (41) while MSM also present higher rates of warts of the anogenital area and rectal cancer associated with HPV infection (41). Therefore, regarding the design of vaccination programs, the epidemiological specificities of all adolescents should be taken into account, regardless of gender and sexual behavior.

A general observation in this systematic review concerned the large discrepancy in HPV prevalence rates between urine and swab samples. As mentioned before, the range of values recorded from urine samples was approximately ten times lower than the value rates from swab samples. Consequently, the two sampling methods do not appear to have comparable sensitivity. According to related studies, the detection of HPV DNA in the urine of women using the PCR method appears to have a similar sensitivity to the detection of genetic material of the virus in cervical smears. Furthermore, urine sampling is practically easier for women and is an important alternative approach for women who do not have easy access to gynecological services (42). It is possible, however, that the detection of viral DNA in urine is not as effective in men compared to swabs of the anogenital area due to their anatomical differences and the fact that the prevalence of different subtypes of the virus, viral resistance and type of lesions differ significantly between men and women. Therefore, further investigation is needed regarding the sensitivity and effectiveness of the detection of viral genetic material in male urine (22).

One of the main limitations of this study was the limited number of publications involving non-high-risk male participants, that is, adolescents and young men without symptoms or a history of HPV infections. Moreover, the majority of studies in the current relevant literature concern women, while even in many studies that included men, the data regarding the prevalence of the virus, their age group or their medical history was not clear. Another limitation was the heterogeneity in reported data on overall HPV prevalence and individual subtypes. Thus, some studies report overall prevalence data for both high- or low-risk types while others report data for specific groups of subtypes, such as subtypes included in vaccines, or individual subtypes. As a result, statistical comparison of study results is very difficult and meta-analysis of their data is not feasible.

In general, heterogeneity in the design and methodology of the available studies is a major limitation and more specifically the heterogeneity of the participants' age, sexual orientation and socio-cultural characteristics.

Conclusions

The conclusion of this study is that the prevalence of HPV remains high among teenagers and young men, a fact that requires the immediate redesign of virus prevention activities such as vaccination programs. The results of the analyzed studies and the relevant literature clearly demonstrate the effectiveness of direct vaccinations of young boys in comparison to herd immunity which requires particularly high rates of vaccination coverage of girls. Thus, the majority of studies converge on the need for universal vaccination programs that will involve all young people and adolescents regardless their gender and sexual behavior. These programs should target immunization during preadolescence to ensure that the increase in viral prevalence with the initiation of sexual activity during adolescence and post-adolescence is limited. Finally, the need for further systematic investigation of the epidemiology and physiology of HPV in males through randomized clinical trials is emphasized in order to collect data for the design of improved surveillance and prevention approaches. The full impact of vaccination against HPV is yet to be determined although pan-gender vaccination programs of adolescents would contribute significantly to the prevention of HPV-related disease.

References

1. WHO (2017) 'Human papillomavirus vaccines: WHO position paper, May 2017-Recommendations', *Vaccine*. Elsevier, 35(43), pp. 5753-5755.
2. Bosch, F. X. et al. (2008) 'Epidemiology and Natural History of Human Papillomavirus Infections and Type-Specific Implications in Cervical Neoplasia', *Vaccine*, 26, pp. K1-K16. doi: <https://doi.org/10.1016/j.vaccine.2008.05.064>.
3. de Martel, C. et al. (2017) 'Worldwide burden of cancer attributable to HPV by site, country and HPV type', *International Journal of Cancer*. John Wiley & Sons, Ltd, 141(4), pp. 664-670. doi: <https://doi.org/10.1002/ijc.30716>.
4. Bruni, L. et al. (2021) 'HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010-2019', *Preventive Medicine*, 144, p. 106399. doi: <https://doi.org/10.1016/j.ypmed.2020.106399>.
5. Drolet, M. et al. (2015) 'Population-level impact and herd effects following human papillomavirus vaccination programmes: A systematic review and meta-analysis', *The Lancet Infectious Diseases*, 15(5), pp. 565-580. doi: [10.1016/S1473-3099\(14\)71073-4](https://doi.org/10.1016/S1473-3099(14)71073-4).

6. Arbyn, M., Smith, S. B., et al. (2018) 'Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses', *Bmj. British Medical Journal Publishing Group*, 363.
7. de Oliveira, C. M., Fregnani, J. H. T. G. and Villa, L. L. (2019) 'HPV Vaccine: Updates and Highlights', *Acta Cytologica*, 63(2), pp. 159-168. doi: 10.1159/000497617.
8. WHO (2006) *Comprehensive cervical cancer control: a guide to essential practice*. World Health Organization.
9. Bogaards, J. A. et al. (2015) 'Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: bayesian evidence synthesis', *BMJ : British Medical Journal*, 350, p. h2016. doi: 10.1136/bmj.h2016.
10. Elfström, K. M. et al. (2016) 'Human papillomavirus vaccination of boys and extended catch-up vaccination: effects on the resilience of programs', *The Journal of infectious diseases*. Oxford University Press, 213(2), pp. 199-205.
11. Näsman, A., Du, J. and Dalianis, T. (2020) 'A global epidemic increase of an HPV-induced tonsil and tongue base cancer-potential benefit from a pan-gender use of HPV vaccine', *Journal of internal medicine*. Wiley Online Library, 287(2), pp. 134-152.
12. Prue, G. et al. (2018) 'It is time for universal HPV vaccination', *The Lancet*. Elsevier, 392(10151), pp. 913-914.
13. Cheng, L., Wang, Y. and Du, J. (2020) 'Human papillomavirus vaccines: an updated review', *Vaccines*. Multidisciplinary Digital Publishing Institute, 8(3), p. 391.
14. Page, M. J. et al. (2021) 'The PRISMA 2020 statement: an updated guideline for reporting systematic reviews', *Systematic reviews*. BioMed Central, 10(1), pp. 1-11.
15. Gargano, J. W. et al. (2017) 'Prevalence of genital human papillomavirus in males, United States, 2013-2014', *The Journal of infectious diseases*. Oxford University Press US, 215(7), pp. 1070-1079.
16. Chow, E. P. F. et al. (2021) 'Prevalence of human papillomavirus in young men who have sex with men after the implementation of gender-neutral HPV vaccination: a repeated cross-sectional study', *The Lancet Infectious Diseases*. Elsevier, 21(10), pp. 1448-1457.
17. Lehtinen, T. et al. (2017) 'Human papillomavirus (HPV) prevalence in male adolescents 4 years after HPV-16/18 vaccination', *The Journal of Infectious Diseases*. Oxford University Press US, 216(8), pp. 966-968.
18. Bianchi, S. et al. (2013) 'Detection and genotyping of human papillomavirus in urine samples from unvaccinated male and female adolescents in Italy', *PLoS One*. Public Library of Science San Francisco, USA, 8(11), p. e79719.
19. Sonnenberg, P. et al. (2013) 'Prevalence, risk factors, and uptake of interventions for sexually transmitted infections in Britain: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal)', *The Lancet*. Elsevier, 382(9907), pp. 1795-1806.
20. Hussain, S. et al. (2012) 'Human papillomavirus infection among young adolescents in India: impact of vaccination', *Journal of medical virology*. Wiley Online Library, 84(2), pp. 298-305.
21. O'leary, M. C. et al. (2011) 'HPV type-specific prevalence using a urine assay in unvaccinated male and female 11-to 18-year olds in Scotland', *British Journal of Cancer*. Nature Publishing Group, 104(7), pp. 1221-1226.
22. Weaver, B. A. et al. (2004) 'Evaluation of Genital Sites and Sampling Techniques for Detection of Human Papillomavirus DNA in Men', *The Journal of Infectious Diseases*, 189(4), pp. 677-685. doi: 10.1086/381395.
23. Baussano, I. et al. (2016) 'Human papillomavirus vaccination at a time of changing sexual behavior', *Emerging infectious diseases*. Centers for Disease Control and Prevention, 22(1), p. 18.
24. Kreimer, A. R. et al. (2004) 'Gender differences in sexual biomarkers and behaviors associated with human papillomavirus-16,-18, and-33 seroprevalence', *Sexually transmitted diseases*. JSTOR, pp. 247-256.
25. Chambers, C. et al. (2022) 'Anal Human Papillomavirus Prevalence Among Vaccinated and Unvaccinated Gay, Bisexual, and Other Men Who Have Sex With Men in Canada', *Sexually transmitted diseases*. Wolters Kluwer Health, 49(2), p. 123.
26. Chandler, E. et al. (2018) 'Epidemiology of any and vaccine-type anogenital human papillomavirus among 13-26-year-old young men after HPV vaccine introduction', *Journal of Adolescent Health*. Elsevier, 63(1), pp. 43-49.
27. Edelstein, M. et al. (2019) 'Implementation and evaluation of the human papillomavirus (HPV) vaccination pilot for men who have sex with men (MSM), England, April 2016 to March 2017', *Eurosurveillance*. European Centre for Disease Prevention and Control, 24(8), p. 1800055.
28. Zou, H. et al. (2016) 'Antibody responses following incident anal and penile infection with human papillomavirus in teenage men who have sex with men', *International Journal of Cancer*. Wiley Online Library, 139(3), pp. 639-646.
29. Nyitray, A. G. et al. (2011) 'The prevalence of genital HPV and factors associated with oncogenic HPV among men having sex with men and men having sex with women and men: the HIM study', *Sexually transmitted diseases*. NIH Public Access, 38(10), p. 932.
30. Giuliano, A. R. et al. (2015) 'EUROGIN 2014 roadmap: Differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection', *International Journal of Cancer*. John Wiley & Sons, Ltd, 136(12), pp. 2752-2760. doi: <https://doi.org/10.1002/ijc.29082>.
31. Partridge JM, Hughes JP, Feng Q, Winer RL, Weaver BA, Xi LF, Stern ME, Lee SK, O'Reilly SF, Hawes SE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students. *J Infect Dis*. 2007 Oct 15;196(8):1128-36. doi: 10.1086/521192. Epub 2007 Sep 13. PMID: 17955430.
32. Vardas E, Giuliano AR, Goldstone S, Palefsky JM, Moreira ED Jr, Penny ME, Aranda C, Jessen H, Moi H, Ferris DG, Liaw KL, Marshall JB, Vuocolo S, Barr E, Haupt RM, Garner EI, Guris D. External genital human papillomavirus prevalence and associated factors among heterosexual men on 5 continents. *J Infect Dis*. 2011 Jan 1;203(1):58-65. doi: 10.1093/infdis/jiq015. PMID: 21148497; PMCID: PMC3086430.
33. Parada R, Morales R, Giuliano AR, Cruz A, Castellsagué X, Lazcano-Ponce E. Prevalence, concordance and determinants of human papillomavirus infection among heterosexual partners in a rural region in central Mexico. *BMC Infect Dis*. 2010 Jul 28;10:223. doi: 10.1186/1471-2334-10-223. Erratum in: *BMC Infect Dis*. 2011;11:25. PMID: 20667085; PMCID: PMC2941497.
34. Wendland, E. M. et al. (2020) 'Prevalence of HPV infection among sexually active adolescents and young adults in Brazil: The POP-Brazil Study', *Scientific reports*. Nature Publishing Group, 10(1), pp. 1-10.
35. Wittawatmongkol, O. et al. (2019) 'Human papillomavirus infection among male adolescents and young adults with perinatally-acquired HIV and without HIV in Thailand', *International journal of STD & AIDS*. SAGE Publications Sage UK: London, England, 30(10), pp. 960-968.
36. Giuliano, A. R. et al. (2008) 'Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men', *The Journal of infectious diseases*. The University of Chicago Press, 198(6), pp. 827-835.
37. Rodríguez-Álvarez, M. I. et al. (2018) 'Prevalence and Risk Factors of Human Papillomavirus in Male Patients: A Systematic Review and Meta-Analysis', *International Journal of Environmental Research and Public Health*. doi: 10.3390/ijerph15102210.
38. Drolet, M. et al. (2019) 'Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis', *The Lancet*, 394(10197), pp. 497-509. doi: [https://doi.org/10.1016/S0140-6736\(19\)30298-3](https://doi.org/10.1016/S0140-6736(19)30298-3).
39. Mehanna, H. et al. (2019) 'Human Papillomavirus (HPV) Vaccine Effectiveness and Potential Herd Immunity for Reducing Oncogenic Oropharyngeal HPV-16 Prevalence in the United Kingdom: A Cross-sectional Study', *Clinical Infectious Diseases*, 69(8), pp. 1296-1302. doi: 10.1093/cid/ciy1081.
40. Wolff, E. et al. (2018) 'Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour', *Vaccine*, 36(34), pp. 5160-5165. doi: <https://doi.org/10.1016/j.vaccine.2018.07.018>.
41. Daling, J. R. et al. (2004) 'Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer', *Cancer*. Wiley Online Library, 101(2), pp. 270-280.
42. Arbyn, M., Xu, L., et al. (2018) 'Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors', *Cochrane database of systematic reviews*. John Wiley & Sons, Ltd, (5).